Quick Links
Privacy Policy
Terms & Conditions
Executive Board
Faculty Portal
Google +
Regus World Trade Centre
Muelle de Barcelona, edif. Sur, 2ª Planta
Barcelona Cataluña
08039 Spain
P: 1-609-378-3701

Copyright © 2018
Physicians’ Education Resource ®, LLC.
All rights reserved.

2nd Annual Paris Breast Cancer Conference™

2nd Annual Paris Breast Cancer Conference™

16-17 November, 2018
Paris, France

The Westin Paris-Vendôme
3 Rue de Castiglione
Paris, 75001, France
Tel: +33 (0) 1 44 77 11 11




click to View Brochure and Agenda

New agents, emerging strategies, and optimization of established regimens are changing the delivery of breast cancer therapy. Over the past decade, tremendous progress in the treatment of breast cancers has led to improved outcomes for patients, but has also complicated clinical management in this setting. We are excited to announce the 2nd Annual Paris Breast Cancer Conference™, a comprehensive educational conference designed to help practitioners place emerging information into the context of landmark clinical trial data and established standards of care, with the goal of ultimately improving the care they provide to their patients with breast cancers.

This practical and interactive multiday program features a faculty of leading international experts who will provide up-to-date information and guidance via didactic lectures, question-and-answer sessions, and extended interactive, case-based panel discussions. This format will enable participants to engage the faculty in a direct exchange of perspectives, personal experiences, and strategies related to clinical challenges in the management of breast cancers.

This meeting is not to be missed! The activity will to continue the legacy and tradition of Physicians’ Education Resource®, LLC, in providing clinicians with the knowledge and confidence to maintain state-of-the-art care and to optimize outcomes for patients with cancer.

Can't-Miss Topics

  • Perspectives on emerging strategies
    • Immunotherapeutics for early-stage, triple-negative breast cancer (TNBC)
    • Antibody-drug conjugates in metastatic TNBC
    • Molecular testing for early human epidermal growth factor receptor 2 (HER2)-positive breast cancer
    • Targeted therapies for HER2-positive metastatic breast cancer
    • Robot-assisted surgery
    • Short preoperative systemic therapy for early luminal breast cancer
    • Genomics for hormone-receptor (HR)‒positive, metastatic breast cancer
  • Patient selection for carboplatin in early TNBC
  • How to treat residual TNBC after neoadjuvant chemotherapy
  • Germline alteration testing in TNBC
  • Clinical updates on targeted therapies including T-DM1, PI3K inhibitors, PARP inhibitors, CDK4/6 inhibition, and HER2-targeted agents
  • Management of brain metastases
  • Treatment de-escalation for small HER2-positive tumors
  • Updates in locoregional therapies
  • Practical guidance on individualizing and optimizing therapy, including endocrine and anthracycline-free regimens
  • Challenging case debates
  • And more!

Benefits of Attending

  • Incorporate the latest data on targeted therapies into practice
  • Challenge the experts with your most difficult cases
  • Learn new frontiers for metastatic and triple-negative disease
  • Connect with top minds in the management of breast cancer
  • Learn updates to guidelines, management, and personalized care

Target Audience

This educational activity is directed toward health care professionals who practice primarily outside of the United States. It is specifically designed for medical oncologists and other health care professionals (physicians, physicians-in-training, oncology nurses, pharmacists, physicians' assistants, etc) involved in the treatment and management of patients with breast cancer.

Educational Objectives:

At the conclusion of this activity, participants should be better prepared to:

  • Incorporate current guidelines and recent data on local and locoregional therapies into the treatment of patients with breast cancer
  • Integrate biomarkers, molecular assays, and other risk assessment tools in treatment decision making for breast cancer appropriately
  • Review current standards and emerging data regarding systemic therapies for the treatment of early-stage, locally advanced, and metastatic breast cancer
  • Consider therapeutic effectiveness, as well as patient and tumor characteristics, in individualizing treatment plans for patients receiving systemic therapies for breast cancer
  • Identify appropriate clinical trials designed to benefit patients with breast cancer

Program Chair

Fabrice André, MD, PhD
Professor in the Department of Medical Oncology,
Institut Gustave Roussy,
Villejuif, France

Nicholas Turner, MD, PhD
Academic Consultant Medical Oncologist Biomedical Research Centre
The Royal Marsden NHS Foundation Trust
The Institute of Cancer Research
London, United Kingdom

Become a Member

Forgot Password?
Calendar of Events
Filter By